High Density SNP Array Analysis of Tyrosine Kinase Inhibitor (TKI) Resistant Chronic Myeloid Leukemia (CML) Shows Secondary Genomic Alterations

被引：0
|
作者：
Nowak, Daniel [1 ]
Kawamata, Norihiko [1 ]
Akagi, Tadayuki [1 ]
Okamoto, Ryoko [1 ]
Thoennissen, Nils [1 ]
Hofmann, Wolf-Karsten [2 ]
Kato, Motohiro [3 ]
Haferlach, Torsten [4 ]
Ogawa, Seishi [3 ]
Koeffler, H. Phillip [1 ]
机构：
[1] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA USA
[2] Charite, Dept Hematol & Oncol, Berlin, Germany
[3] Univ Tokyo, Tokyo, Japan
[4] MLL Munchner Leukamie Labor GmbH, Munich, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1091 / 1092
页数：2
相关论文
共 50 条
  • [1] SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
    Nowak, Daniel
    Ogawa, Seishi
    Mueschen, Markus
    Kato, Motohiro
    Kawamata, Norihiko
    Meixel, Antonie
    Nowak, Verena
    Kim, Han S.
    Kang, Sharon
    Paquette, Ronald
    Chang, Mi-Sook
    Thoenissen, Nils H.
    Mossner, Max
    Hofmann, Wolf-Karsten
    Kohlmann, Alexander
    Weiss, Tamara
    Haferlach, Torsten
    Haferlach, Claudia
    Koeffler, H. Phillip
    BLOOD, 2010, 115 (05) : 1049 - 1053
  • [2] SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations (vol 115, pg 1049, 2010)
    Nowak, D.
    Ogawa, S.
    Mueschen, M.
    BLOOD, 2010, 115 (19) : 4006 - 4006
  • [3] Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
    Haznedaroglu, Ibrahim C.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
  • [4] Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
    Barber, Mary C.
    Mauro, Michael J.
    Moslehi, Javid
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 110 - 114
  • [5] A Role for Lipid Metabolism in Tyrosine Kinase Inhibitor (TKI) Resistance of Chronic Myeloid Leukemia (CML)
    Gonzalez, Mayra A.
    Lopez, Jose L.
    Schenkel, Katherine
    Reffell, Kelaiah
    A.Eide, Christopher
    Bajpeyi, Sudip
    M.Eiring, Anna
    BLOOD, 2021, 138
  • [6] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
    Ciftciler, R.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7787 - 7798
  • [7] Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).
    Chen, Yaozhu J.
    Huang, Hui
    Divino, Victoria
    Pokras, Shibani
    Hallinan, Shawn
    Munakata, Julie
    Taylor, Catherine
    McGarry, Lisa
    Ng, Daniel
    Nieset, Christopher
    Knopf, Kevin B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)
    Nodzon, Lisa
    Tinsley-Vance, Sara
    BLOOD, 2017, 130
  • [9] THREE NEW MUTATIONS FOUND IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS (TKI)
    Mascarenhas, C. Couto
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 572 - 572
  • [10] An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies
    Guilhot, Francois
    Coombs, John
    Szczudlo, Tomasz
    Zernovak, Oleg
    Macdonald, Nancy J.
    Shapiro, Ari
    BLOOD, 2010, 116 (21) : 176 - 177
12345